Retargeting of adenovirus vectors through genetic fusion of a single-chain or single-domain antibody to capsid protein IX

Journal of Virology

Volumn 84, Issue 19, 2010, Pages 10074-10086

  Poulin, Kathy L ^a   Lanthier, Robert M ^a,b   Smith, Adam C ^a   Christou, Carin ^a   Quiroz, Milagros Risco ^a   Powell, Karen L ^a   O'Meara, Ryan W ^a,b,c   Kothary, Rashmi ^a,b,c   Lorimer, Ian A ^a,b   Parks, Robin J ^a,b  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CAPSID PROTEIN; CAPSID PROTEIN 9; EPITOPE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR VIII; HYBRID PROTEIN;

ARTICLE; CONTROLLED STUDY; ENDOPLASMIC RETICULUM; GENE FUSION; GENE TARGETING; HUMAN; HUMAN CELL; IMMUNOBLOTTING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; ADENOVIRIDAE; ANIMAL; CELL LINE; CHEMISTRY; CHO CELL LINE; CRICETULUS; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; HAMSTER; IMMUNOLOGY; METABOLISM; NUCLEOTIDE SEQUENCE; PLASMID; PROTEIN ENGINEERING;

ADENOVIRIDAE; MIRIDAE;

ADENOVIRIDAE; ANIMALS; ANTIBODIES; BASE SEQUENCE; CAPSID PROTEINS; CELL LINE; CHO CELLS; CRICETINAE; CRICETULUS; ENDOPLASMIC RETICULUM; EPITOPES; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HUMANS; PLASMIDS; PROTEIN ENGINEERING; PROTEIN FOLDING; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; SINGLE-CHAIN ANTIBODIES; TRANSDUCTION, GENETIC;

EID: 77956807939     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02665-09     Document Type: Article

References (86)

1. Addison, C. L., M. Hitt, D. Kunsken, and F. L. Graham. 1997. Comparison of the human versus murine cytomegalovirus immediate early gene promoters for transgene expression by adenoviral vectors. J. Gen. Virol. 78:1653-1661.
2. Amalfitano, A., and R. J. Parks. 2002. Separating fact from fiction: assessing the potential of modified adenovirus vectors for use in human gene therapy. Curr. Gene Ther. 2:111-133.
3. Beckman, R. A., L. M. Weiner, and H. M. Davis. 2007. Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors. Cancer 109:170-179.
4. Bergelson, J. M., J. A. Cunningham, G. Droguett, E. A. Kurt-Jones, A. Krithivas, J. S. Hong, M. S. Horwitz, R. L. Crowell, and R. W. Finberg. 1997. Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 275:1320-1323.
5. Bett, A. J., W. Haddara, L. Prevec, and F. L. Graham. 1994. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc. Natl. Acad. Sci. U. S. A. 91:8802-8806.
6. Boulanger, P., P. Lemay, G. E. Blair, and W. C. Russell. 1979. Characterization of adenovirus protein IX. J. Gen. Virol. 44:783-800.
7. Bramson, J. L., N. Grinshtein, R. A. Meulenbroek, J. Lunde, D. Kottachchi, I. A. Lorimer, B. J. Jasmin, and R. J. Parks. 2004. Helper-dependent adenoviral vectors containing modified fibre for improved transduction of developing and mature muscle cells. Hum. Gene Therapy 15:179-188.
8. Campbell, R. E., O. Tour, A. E. Palmer, P. A. Steinbach, G. S. Baird, D. A. Zacharias, and R. Y. Tsien. 2002. A monomeric red fluorescent protein. Proc. Natl. Acad. Sci. U. S. A. 99:7877-7882.
9. Campos, S. K., and M. A. Barry. 2006. Comparison of adenovirus fiber, protein IX, and hexon capsomeres as scaffolds for vector purification and cell targeting. Virology 349:453-462.
10. Campos, S. K., M. B. Parrott, and M. A. Barry. 2004. Avidin-based targeting and purification of a protein IX-modified, metabolically biotinylated adenoviral vector. Mol. Ther. 9:942-954.
11. Carette, J. E., H. C. Graat, F. H. Schagen, M. A. Abou El Hassan, W. R. Gerritsen, and V. W. van Beusechem. 2005. Replication-dependent transgene expression from a conditionally replicating adenovirus via alternative splicing to a heterologous splice-acceptor site. J. Gene Med. 7:1053-1062.
12. Chan, C. H., and C. P. Stanners. 2007. Recent advances in the tumour biology of the GPI-anchored carcinoembryonic antigen family members CEACAM5 and CEACAM6. Curr. Oncol. 14:70-73.
13. Chartier, C., E. Degryse, M. Gantzer, A. Dieterle, A. Pavirani, and M. Mehtali. 1996. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J. Virol. 70:4805-4810. (Pubitemid 26187479)
14. Colby, W. W., and T. Shenk. 1981. Adenovirus type 5 virions can be assembled in vivo in the absence of detectable polypeptide IX. J. Virol. 39:977-980.
15. Corjon, S., A. Wortmann, T. Engler, N. van Rooijen, S. Kochanek, and F. Kreppel. 2008. Targeting of adenovirus vectors to the LRP receptor family with the high-affinity ligand RAP via combined genetic and chemical modification of the pIX capsomere. Mol. Ther. 16:1813-1824.
16. Cottet, S., and B. Corthesy. 1997. Cellular processing limits the heterologous expression of secretory component in mammalian cells. Eur. J. Biochem. 246:23-31.
17. Demarest, S. J., and S. M. Glaser. 2008. Antibody therapeutics, antibody engineering, and the merits of protein stability. Curr. Opin. Drug Discov. Devel. 11:675-687.
18. de Vrij, J., T. G. Uil, S. K. van den Hengel, S. J. Cramer, D. Koppers-Lalic, M. C. Verweij, E. J. Wiertz, J. Vellinga, R. A. Willemsen, and R. C. Hoeben. 2008. Adenovirus targeting to HLA-A1/MAGE-A1-positive tumor cells by fusing a single-chain T-cell receptor with minor capsid protein IX. Gene Ther. 15:978-989.
19. Dmitriev, I., V. Krasnykh, C. R. Miller, M. Wang, E. Kashentseva, G. Mikheeva, N. Belousova, and D. T. Curiel. 1998. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J. Virol. 72:9706-9713.
20. Dmitriev, I. P., E. A. Kashentseva, and D. T. Curiel. 2002. Engineering of adenovirus vectors containing heterologous peptide sequences in the C terminus of capsid protein IX. J. Virol. 76:6893-6899.
21. Einfeld, D. A., R. Schroeder, P. W. Roelvink, A. Lizonova, C. R. King, I. Kovesdi, and T. J. Wickham. 2001. Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions. J. Virol. 75:11284-11291.
22. Fabry, C. M., M. Rosa-Calatrava, C. Moriscot, R. W. Ruigrok, P. Boulanger, and G. Schoehn. 2009. The C-terminal domains of adenovirus serotype 5 protein IX assemble into an antiparallel structure on the facets of the capsid. J. Virol. 83:1135-1139.
23. Furcinitti, P. S., J. van Oostrum, and R. M. Burnett. 1989. Adenovirus polypeptide IX revealed as capsid cement by difference images from electron microscopy and crystallography. EMBO J. 8:3563-3570.
24. Glasgow, J. N., M. Everts, and D. T. Curiel. 2006. Transductional targeting of adenovirus vectors for gene therapy. Cancer Gene Ther. 13:830-844.
25. Graham, F. L. 1987. Growth of 293 cells in suspension culture. J. Gen. Virol. 68:937-940.
26. Graham, F. L., J. Smiley, W. C. Russell, and R. Nairn. 1977. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36:59-74.
27. Guo, Z. S., L. H. Wang, R. C. Eisensmith, and S. L. Woo. 1996. Evaluation of promoter strength for hepatic gene expression in vivo following adenovirus-mediated gene transfer. Gene Ther. 3:802-810.
28. He, T. C., S. Zhou, L. T. da Costa, J. Yu, K. W. Kinzler, and B. Vogelstein. 1998. A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. U. S. A. 95:2509-2514.
29. Hubberstey, A. V., M. Pavliv, and R. J. Parks. 2002. Cancer therapy utilizing an adenoviral vector expressing only E1A. Cancer Gene Ther. 9:321-329.
30. Jakubczak, J. L., M. L. Rollence, D. A. Stewart, J. D. Jafari, D. J. Von Seggern, G. R. Nemerow, S. C. Stevenson, and P. L. Hallenbeck. 2001. Adenovirus type 5 viral particles pseudotyped with mutagenized fiber proteins show diminished infectivity of coxsackie B-adenovirus receptor-bearing cells. J. Virol. 75:2972-2981.
31. Jooss, K., Y. Yang, K. J. Fisher, and J. M. Wilson. 1998. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J. Virol. 72:4212-4223.
32. Kalderon, D., W. D. Richardson, A. F. Markham, and A. E. Smith. 1984. Sequence requirements for nuclear location of simian virus 40 large-T antigen. Nature 311:33-38.
33. Kalyuzhniy, O., N. C. Di Paolo, M. Silvestry, S. E. Hofherr, M. A. Barry, P. L. Stewart, and D. M. Shayakhmetov. 2008. Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc. Natl. Acad. Sci. U. S. A. 105:5483-5488.
34. Kim, I., W. Xu, and J. C. Reed. 2008. Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat. Rev. Drug Discov. 7:1013-1030.
35. Kirby, I., E. Davison, A. J. Beavil, C. P. Soh, T. J. Wickham, P. W. Roelvink, I. Kovesdi, B. J. Sutton, and G. Santis. 2000. Identification of contact residues and definition of the CAR-binding site of adenovirus type 5 fiber protein. J. Virol. 74:2804-2813.
36. Krasnykh, V., I. Dmitriev, G. Mikheeva, C. R. Miller, N. Belousova, and D. T. Curiel. 1998. Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob. J. Virol. 72:1844-1852.
37. Kreppel, F., J. Gackowski, E. Schmidt, and S. Kochanek. 2005. Combined genetic and chemical capsid modifications enable flexible and efficient deand retargeting of adenovirus vectors. Mol. Ther. 12:107-117.
38. Le, L. P., M. Everts, I. P. Dmitriev, J. G. Davydova, M. Yamamoto, and D. T. Curiel. 2004. Fluorescently labeled adenovirus with pIX-EGFP for vector detection. Mol. Imaging 3:105-116.
39. Li, J., L. Le, D. A. Sibley, J. M. Mathis, and D. T. Curiel. 2005. Genetic incorporation of HSV-1 thymidine kinase into the adenovirus protein IX for functional display on the virion. Virology 338:247-258.
40. Lorimer, I. A. 2002. Mutant epidermal growth factor receptors as targets for cancer therapy. Curr. Cancer Drug Targets 2:91-102.
41. Lorimer, I. A., A. Keppler-Hafkemeyer, R. A. Beers, C. N. Pegram, D. D. Bigner, and I. Pastan. 1996. Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display. Proc. Natl. Acad. Sci. U. S. A. 93:14815-14820.
42. Lorimer, I. A., and S. J. Lavictoire. 2000. Targeting retrovirus to cancer cells expressing a mutant EGF receptor by insertion of a single chain antibody variable domain in the envelope glycoprotein receptor binding lobe. J. Immunol. Methods 237:147-157.
43. Maelandsmo, G. M., P. J. Ross, M. Pavliv, R. A. Meulenbroek, C. Evelegh, D. A. Muruve, F. L. Graham, and R. J. Parks. 2005. Use of a murine secreted alkaline phosphatase as a non-immunogenic reporter gene in mice. J. Gene Med. 7:307-315.
44. Mai, K. T., D. G. Perkins, J. Zhang, and C. R. Mackenzie. 2006. ES1, a new lung carcinoma antibody - an immunohistochemical study. Histopathology 49:515-522.
45. Marsh, M. P., S. K. Campos, M. L. Baker, C. Y. Chen, W. Chiu, and M. A. Barry. 2006. Cryoelectron microscopy of protein IX-modified adenoviruses suggests a new position for the C terminus of protein IX. J. Virol. 80:11881-11886.
46. Matthews, Q. L., D. A. Sibley, H. Wu, J. Li, M. A. Stoff-Khalili, R. Waehler, J. M. Mathis, and D. T. Curiel. 2006. Genetic incorporation of a herpes simplex virus type 1 thymidine kinase and firefly luciferase fusion into the adenovirus protein IX for functional display on the virion. Mol. Imaging 5:510-519.
47. Meulenbroek, R. A., K. L. Sargent, J. Lunde, B. J. Jasmin, and R. J. Parks. 2004. Use of adenovirus protein IX to display large polypeptides on the virion - generation of fluorescent virus through incorporation of pIX-GFP. Mol. Ther. 9:617-624.
48. Michalak, M., J. Groenendyk, E. Szabo, L. I. Gold, and M. Opas. 2009. Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum. Biochem. J. 417:651-666.
49. Muruve, D. A., M. J. Cotter, A. K. Zaiss, L. R. White, Q. Liu, T. Chan, S. A. Clark, P. J. Ross, R. A. Meulenbroek, G. M. Maelandsmo, and R. J. Parks. 2004. Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo. J. Virol. 78:5966-5972.
50. Nakamura, T., K. W. Peng, M. Harvey, S. Greiner, I. A. Lorimer, C. D. James, and S. J. Russell. 2005. Rescue and propagation of fully retargeted oncolytic measles viruses. Nat. Biotechnol. 23:209-214.
51. Nelson, J. E., and M. A. Kay. 1997. Persistence of recombinant adenovirus in vivo is not dependent on vector DNA replication. J. Virol. 71:8902-8907.
52. Niknejad, N., M. Morley, and J. Dimitroulakos. 2007. Activation of the integrated stress response regulates lovastatin-induced apoptosis. J. Biol. Chem. 282:29748-29756.
53. Parks, R. J. 2005. Adenovirus protein IX: a new look at an old protein. Mol. Ther. 11:19-25.
54. Philibert, P., A. Stoessel, W. Wang, A. P. Sibler, N. Bec, C. Larroque, J. G. Saven, J. Courtete, E. Weiss, and P. Martineau. 2007. A focused antibody library for selecting scFvs expressed at high levels in the cytoplasm. BMC Biotechnol. 7:81.
55. Pihkala, P., M. Kawahara, H. Ueda, and T. Nagamune. 2004. An antigen-mediated selection system for mammalian cells that produce glycosylated single-chain Fv. Biochem. Biophys. Res. Commun. 324:1165-1172.
56. Roelvink, P. W., G. Mi Lee, D. A. Einfeld, I. Kovesdi, and T. J. Wickham. 1999. Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae. Science 286:1568-1571.
57. Rogers, B. E., J. T. Douglas, C. Ahlem, D. J. Buchsbaum, J. Frincke, and D. T. Curiel. 1997. Use of a novel cross-linking method to modify adenovirus tropism. Gene Ther. 4:1387-1392.
58. Rosa-Calatrava, M., L. Grave, F. Puvion-Dutilleul, B. Chatton, and C. Kedinger. 2001. Functional analysis of adenovirus protein IX identifies domains involved in capsid stability, transcriptional activity, and nuclear reorganization. J. Virol. 75:7131-7141. (Pubitemid 32641601)
59. Ross, P. J., and R. J. Parks. 2006. Construction of first-generation adenoviral vectors. In T. Freidman and J. Rossi (ed.), Gene therapy vectors: a techniques manual. Cold Spring Harbor, Cold Spring Harbor, NY.
60. Saban, S. D., M. Silvestry, G. R. Nemerow, and P. L. Stewart. 2006. Visualization of alpha-helices in a 6-angstrom resolution cryoelectron microscopy structure of adenovirus allows refinement of capsid protein assignments. J. Virol. 80:12049-12059.
61. Sargent, K., R. A. Meulenbroek, and R. J. Parks. 2004. Activation of adenoviral gene expression by protein IX is not required for efficient virus replication. J. Virol. 78:5032-5037.
62. Schnell, M. A., Y. Zhang, J. Tazelaar, G. P. Gao, Q. C. Yu, R. Qian, S. J. Chen, A. N. Varnavski, C. LeClair, S. E. Raper, and J. M. Wilson. 2001. Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol. Ther. 3:708-722.
63. Seidman, M. A., S. M. Hogan, R. L. Wendland, S. Worgall, R. G. Crystal, and P. L. Leopold. 2001. Variation in adenovirus receptor expression and adenovirus vector-mediated transgene expression at defined stages of the cell cycle. Mol. Ther. 4:13-21.
64. Seregin, S. S., Y. A. Aldhamen, D. M. Appledorn, Z. C. Hartman, N. J. Schuldt, J. Scott, S. Godbehere, H. Jiang, M. M. Frank, and A. Amalfitano. 28 May 2010. Adenovirus capsid-display of the retro-oriented human complement inhibitor DAF reduces Ad-vector triggered immune responses in vitro and in vivo. Blood doi: 10.1182/blood-2010-03-276949.
65. Seregin, S. S., Z. C. Hartman, D. M. Appledorn, S. Godbehere, H. Jiang, M. M. Frank, and A. Amalfitano. 2010. Novel adenovirus vectors 'capsid-displaying' a human complement inhibitor. J. Innate Immun. 2:353-359.
66. Shayakhmetov, D. M., A. Gaggar, S. Ni, Z. Y. Li, and A. Lieber. 2005. Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J. Virol. 79:7478-7491.
67. Shenk, T. 2001. Adenoviridae: the viruses and their replication, p. 2265-2300. In B. N. Fields, P. M. Howley, D. E. Griffin, R. A. Lamb, M. A. Martin, B. Roizman, S. E. Strauss, and D. M. Knipe (ed.), Fields virology, vol. 67. Lippincott-Raven Publishers, Philadelphia, PA.
68. Silvestry, M., S. Lindert, J. G. Smith, O. Maier, C. M. Wiethoff, G. R. Nemerow, and P. L. Stewart. 2009. Cryo-electron microscopy structure of adenovirus type 2 temperature-sensitive mutant 1 reveals insight into the cell entry defect. J. Virol. 83:7375-7383.
69. Singer, B. B., I. Scheffrahn, R. Kammerer, N. Suttorp, S. Ergun, and H. Slevogt. 2010. Deregulation of the CEACAM expression pattern causes undifferentiated cell growth in human lung adenocarcinoma cells. PLoS One 5:e8747.
70. Smith, A. C., K. L. Poulin, and R. J. Parks. 2009. DNA genome size affects the stability of the adenovirus virion. J. Virol. 83:2025-2028.
71. Smith, J. S., J. R. Keller, N. C. Lohrey, C. S. McCauslin, M. Ortiz, K. Cowan, and S. E. Spence. 1999. Redirected infection of directly biotinylated recombinant adenovirus vectors through cell surface receptors and antigens. Proc. Natl. Acad. Sci. U. S. A. 96:8855-8860.
72. Smith, T. A., N. Idamakanti, M. L. Rollence, J. Marshall-Neff, J. Kim, K. Mulgrew, G. R. Nemerow, M. Kaleko, and S. C. Stevenson. 2003. Adenovirus serotype 5 fiber shaft influences in vivo gene transfer in mice. Hum. Gene Ther. 14:777-787.
73. Snitkovsky, S., T. M. Niederman, B. S. Carter, R. C. Mulligan, and J. A. Young. 2000. A TVA-single-chain antibody fusion protein mediates specific targeting of a subgroup A avian leukosis virus vector to cells expressing a tumor-specific form of epidermal growth factor receptor. J. Virol. 74:9540-9545.
74. Tang, Y., L. P. Le, Q. L. Matthews, T. Han, H. Wu, and D. T. Curiel. 2008. Derivation of a triple mosaic adenovirus based on modification of the minor capsid protein IX. Virology 377:391-400.
75. Tanha, J., G. Dubuc, T. Hirama, S. A. Narang, and C. R. MacKenzie. 2002. Selection by phage display of llama conventional V(H) fragments with heavy chain antibody V(H)H properties. J. Immunol. Methods 263:97-109.
76. Tomko, R. P., R. Xu, and L. Philipson. 1997. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc. Natl. Acad. Sci. U. S. A. 94:3352-3356.
77. Vellinga, J., J. de Vrij, S. Myhre, T. Uil, P. Martineau, L. Lindholm, and R. C. Hoeben. 2007. Efficient incorporation of a functional hyper-stable single-chain antibody fragment protein-IX fusion in the adenovirus capsid. Gene Ther. 14:664-670.
78. Vellinga, J., M. J. Rabelink, S. J. Cramer, D. J. van den Wollenberg, H. Van der Meulen, K. N. Leppard, F. J. Fallaux, and R. C. Hoeben. 2004. Spacers increase the accessibility of peptide ligands linked to the carboxyl terminus of adenovirus minor capsid protein IX. J. Virol. 78:3470-3479.
79. Vigne, E., I. Mahfouz, J. F. Dedieu, A. Brie, M. Perricaudet, and P. Yeh. 1999. RGD inclusion in the hexon monomer provides adenovirus type 5-based vectors with a fiber knob-independent pathway for infection. J. Virol. 73:5156-5161.
80. Waddington, S. N., J. H. McVey, D. Bhella, A. L. Parker, K. Barker, H. Atoda, R. Pink, S. M. K. Buckley, J. A. Greig, L. Denby, J. Custers, T. Morita, I. M. B. Francischetti, R. Q. Monteiro, D. H. Barouch, N. van Rooijen, C. Napoli, M. J. E. Havenga, S. A. Nicklin, and A. H. Baker. 2008. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 132:397-409.
81. Wickham, T. J., P. Mathias, D. A. Cheresh, and G. R. Nemerow. 1993. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 73:309-319.
82. Wickham, T. J., D. M. Segal, P. W. Roelvink, M. E. Carrion, A. Lizonova, G. M. Lee, and I. Kovesdi. 1996. Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. J. Virol. 70:6831-6838.
83. Wickham, T. J., E. Tzeng, L. L. Shears, P. W. Roelvink, Y. Li, G. M. Lee, D. E. Brough, A. Lizonova, and I. Kovesdi. 1997. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J. Virol. 71:8221-8229.
84. Wörn, A., and A. Pluckthun. 2001. Stability engineering of antibody singlechain Fv fragments. J. Mol. Biol. 305:989-1010.
85. Zakhartchouk, A., W. Connors, A. van Kessel, and S. K. Tikoo. 2004. Bovine adenovirus type 3 containing heterologous protein in the C-terminus of minor capsid protein IX. Virology 320:291-300.
86. Zhang, J., Q. Li, T. D. Nguyen, T. L. Tremblay, E. Stone, R. To, J. Kelly, and C. Roger MacKenzie. 2004. A pentavalent single-domain antibody approach to tumor antigen discovery and the development of novel proteomics reagents. J. Mol. Biol. 341:161-169.